CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
REVENUES:
License fees	$ 2,218,174	$ 899,998	$ 263,757
Royalties from product sales	366,775	541,681	756,950
Grant income	1,573,329	2,222,458	2,767,181
Sale of research products	276,058	251,190	646,271
Total revenues	4,434,336	3,915,327	4,434,159
Cost of sales	(792,659)	(434,271)	(79,397)
Total revenues, net	3,641,677	3,481,056	4,354,762
EXPENSES:
Research and development	(26,609,423)	(18,116,688)	(13,699,691)
Acquired in-process research and development	(17,458,766)	0	0
General and administrative	(15,558,674)	(10,365,045)	(9,341,502)
Total expenses	(59,626,863)	(28,481,733)	(23,041,193)
Loss from operations	(55,985,186)	(25,000,677)	(18,686,431)
OTHER INCOME (EXPENSES):
Interest income/(expense), net	(578)	19,383	29,727
Gain/(loss) on sale of fixed assets	5,120	(6,856)	(6,246)
Other income/(expense), net	(209,177)	(317,710)	219,067
Total other income/(expenses), net	(204,635)	(305,183)	242,548
DEFERRED NET LOSS BEFORE INCOME TAX BENEFITS	(56,189,821)	(25,305,860)	(18,443,883)
Deferred income tax benefit	3,280,695	0	0
NET LOSS	(52,909,126)	(25,305,860)	(18,443,883)
Net loss attributable to the noncontrolling interest	9,026,291	3,880,157	1,928,383
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(43,882,835)	(21,425,703)	(16,515,500)
Foreign currency translation gain/(loss)	119,469	63,179	(1,020,087)
Unrealized gain on available-for-sale securities, net	3,000	0	0
COMPREHENSIVE LOSS	$ (43,760,366)	$ (21,362,524)	$ (17,535,587)
BASIC AND DILUTED LOSS PER COMMON SHARE (in dollars per share)	$ (0.81)	$ (0.44)	$ (0.35)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)	54,226,219	49,213,687	47,053,518